(CercleFinance.com) – Cellectis announced on Friday that its product candidate UCART22 had been administered to a first patient as part of a study dedicated to the treatment of acute lymphoblastic leukemia.
The biotechnology company, specializing in genome editing, indicates that its product was administered for the first time to a patient in the United States, after a 28-day observation period, without complications.
In a press release, Cellectis evokes a ‘major milestone’ for the company, hoping to be able to offer a potential therapeutic alternative for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)
Manufactured in-house, UCART22 is an allogeneic CAR T product candidate that targets the CD22 antigen being evaluated in a Phase 1/2a clinical trial to assess the safety and clinical activity of the product candidate in patients with ALL relapsed or refractory B-cells.
Cellectis recalls having made the decision three years ago to build its own facilities in Raleigh, North Carolina and Paris in order to take control of its production and manufacturing times.
Listed on the Paris Stock Exchange, Cellectis shares climbed more than 7% late Friday morning.